<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Iran J Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">Iran J Med Sci</journal-id><journal-id journal-id-type="publisher-id">IJMS</journal-id><journal-title-group><journal-title>Iranian Journal of Medical Sciences</journal-title></journal-title-group><issn pub-type="ppub">0253-0716</issn><issn pub-type="epub">1735-3688</issn><publisher><publisher-name>Shiraz University of Medical Sciences</publisher-name><publisher-loc>Shiraz, Iran</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">ijms-39-536</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>
Blockade of Central Angiotensin II AT<sub>1</sub> Receptor Protects the Brain from Ischemia/Reperfusion Injury in Normotensive Rats
</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Panahpour</surname><given-names>Hamdolah</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Nekooeian</surname><given-names>Ali Akbar</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Dehghani</surname><given-names>Gholam Abbas</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff3">3</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Physiology and Pharmacology, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran;
</aff><aff id="aff2"><label>2</label>Department of Pharmacology, School of Medicine, Shiraz University of Medical Sciences, Shiraz. Iran;
</aff><aff id="aff3"><label>3</label>Department of Physiology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
</aff><author-notes><corresp id="cor">Correspondence: Hamdolah Panahpour, PhD; Department of Physiology and pharmacology, School of Medicine, Daneshgah Street, P. O. Box: 56197, Ardabil, Iran Tel/Fax: +98 451 5510057 Email: h.panahpour@arums.ac.ir </corresp></author-notes><pub-date pub-type="ppub"><month>11</month><year>2014</year></pub-date><volume>39</volume><issue>6</issue><fpage>536</fpage><lpage>542</lpage><history><date date-type="received"><day>14</day><month>2</month><year>2014</year></date><date date-type="rev-recd"><day>25</day><month>3</month><year>2014</year></date><date date-type="accepted"><day>27</day><month>4</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; 2014: Iranian Journal of Medical Sciences</copyright-statement><license><license-p>
This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
</license-p></license></permissions><abstract><p>
<bold>Background: </bold>Stroke is the third leading cause of invalidism and death in industrialized countries. There are conflicting reports about the effects of Angiotensin II on ischemia-reperfusion brain injuries and most data have come from chronic hypertensive rats. In this study, hypotensive and non-hypotensive doses of candesartan were used to investigate the effects of angiotensin II AT<sub>1</sub> receptor blockade by transient focal cerebral ischemia in normotensive rats.
</p><p>
<bold>Methods:</bold> In this experimental study, 48 male Sprague-Dawley rats were randomly divided into four groups (n=12). Sham group, the control ischemic group, and two ischemic groups received candesartan at doses of 0.1 or 0.5 mg/kg at one hour before ischemia. Transient focal cerebral ischemia was induced by 60 minutes occlusion of the middle cerebral artery, followed by 24 h reperfusion. The neurological deficit score was evaluated at the end of the reperfusion period. The total cortical and striatal infarct volumes were determined using triphenyltetrazolium chloride staining technique. Tissue swelling was calculated for the investigation of ischemic brain edema formation.
</p><p>
<bold>Results:</bold> In comparison with the control ischemic group, AT<sub>1</sub> receptor blockade with both doses of candesartan (0.1 or 0.5 mg/kg) significantly improved neurological deficit and lowered cortical and striatal infarct sizes. In addition, pretreatment with candesartan significantly reduced ischemia induced tissue swelling.
</p><p>
<bold>Conclusion:</bold> Angiotensin II by stimulating AT<sub>1</sub> receptors, participates in ischemia-reperfusion injuries and edema formation. AT<sub>1</sub> receptor blockade with candesartan decreased ischemic brain injury and edema and improved neurological outcome.
</p></abstract><kwd-group><title>Keywords</title><kwd>Angiotensin II</kwd><kwd>Angiotensin AT1 receptor</kwd><kwd>Candesartan</kwd><kwd>Stroke</kwd><kwd>Rat</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>
Ischemic stroke remains one of the main illnesses with a major health and economic impact, and greatly consumes medical resources. With a mortality rate of around 30%, stroke remains the third leading cause of invalidism and death in industrialized countries. Ischemic brain injury is the result of a complex sequence of pathophysiological events that develops over time and space.<sup><xref rid="B1" ref-type="bibr">1</xref></sup> Brain edema is a life-threatening complication of cerebral infarction and aggravates the primary ischemic injury to the brain.<sup><xref rid="B2" ref-type="bibr">2</xref></sup><sup>,</sup><sup><xref rid="B3" ref-type="bibr">3</xref></sup> It is suggested that the prevention of ischemic brain edema formation reduces neuronal injury following cerebral ischemia.<sup><xref rid="B4" ref-type="bibr">4</xref></sup>
</p><p>
Beside its multiple physiological functions, renin-angiotensin system (RAS) has been implicated in pathogenesis and outcome of ischemic injuries in vital organs such as heart<sup><xref rid="B5" ref-type="bibr">5</xref></sup> and kidney.<sup><xref rid="B6" ref-type="bibr">6</xref></sup> Furthermore, it is suggested that RAS may contribute in stroke related pathogenic mechanisms and involve in the ischemic brain damage.<sup><xref rid="B7" ref-type="bibr">7</xref></sup> However, the role of RAS in ischemic brain injuries is controversial. Initial studies suggested a protective role for RAS activity in cerebral ischemia but later reports postulated a correlation between Angiotensin (Ang) II and the severity of ischemic injury. Previous studies demonstrated that inhibition of angiotensin converting enzyme by enalapril pretreatment<sup><xref rid="B8" ref-type="bibr">8</xref></sup> and treatment.<sup><xref rid="B9" ref-type="bibr">9</xref></sup> Furthermore, the reduction of Ang II improved neurological outcome and reduced brain injuries in animal models of focal cerebral ischemia. Most of the physiological action of Ang II has been shown to be mediated by the AT<sub>1 </sub>receptors.<sup><xref rid="B10" ref-type="bibr">10</xref></sup> Consequently, this study is designed to investigate the role of RAS activity and its effector peptide, Ang II in conjunction with AT<sub>1</sub> receptors in brain injuries and edema following transient focal cerebral ischemia in rats.
</p><p>
In this study, candesartan as an AT1 antagonist was used for AT<sub>1</sub> receptor blocking. It has been demonstrated that candesartan can easily penetrate the blood brain barrier (BBB) to inhibit the effects of central Ang II. The long-lasting blockade of central AT<sub>1</sub> receptors by candesartan may be attributed to its tight binding and slow dissociation from AT<sub>1</sub> receptors.<sup><xref rid="B11" ref-type="bibr">11</xref></sup><sup>,</sup><sup><xref rid="B12" ref-type="bibr">12</xref></sup> Therefore, the effective and long-lasting blockade of central AT<sub>1</sub> receptors is produced by candesartan.
</p><p>
The present study uses an intraluminal filament method that induces transient focal cerebral ischemia by middle cerebral artery occlusion (MCAO) in a rat.<sup><xref rid="B8" ref-type="bibr">8</xref></sup><sup>,</sup><sup><xref rid="B9" ref-type="bibr">9</xref></sup> This model is less invasive and reperfusion of the ischemic region is feasible. It is comparable with human stroke, in which spontaneous or drug-induced reperfusion occurs. Furthermore, most data about the participation of RAS in cerebral ischemia have originated from chronic hypertensive rats.<sup><xref rid="B13" ref-type="bibr">13</xref></sup><sup>-</sup><sup><xref rid="B15" ref-type="bibr">15</xref></sup> Pathologic remodeling of cerebral vessels that occur during chronic hypertension are believed to interfere with the outcomes of neuroprotective agents.<sup><xref rid="B15" ref-type="bibr">15</xref></sup> To exclude these possibilities, the model of transient focal cerebral ischemia in normotensive rats was used.
</p></sec><sec sec-type="materials|methods"><title>Materials and Methods</title><p>Male Sprague-Dawley rats (300-380g) were obtained from the central animal shelter facility of Shiraz Medical Sciences University (Shiraz, Iran). All protocols of the study were approved by the Institutional Animal Ethics Committee of Shiraz University of Medical Sciences, which follows the National Institutes of Health guidelines for care and use of animals. Animals were housed at room temperature of 22-24&#x000b0;C, humidity of 40-60% and light period of 07.00-19.00 controlled environments. The animals had access to tap water and rat chow, but only had free access to tap water on the night before surgery. They were anesthetized with IP injections of chloral hydrate (400 mg/kg). Two temperature probes were inserted into the left temporalis muscle and rectum to monitor head and core temperatures. Two separate heating lamps were used to keep the core and cranial temperatures at 37&#x000b1;0.5&#x000b0;C.</p><p>Experimental Design and Protocol</p><p>
<italic>Group I </italic>(sham, n=12): rats underwent surgery in the neck region and received a single IV injection of the vehicle (1 ml/kg, 0.1 normal sodium carbonate solution) without being exposed to MCAO.
</p><p>
<italic>Group II </italic>(control ischemic; n=12): rats received a single IV injection of the vehicle 1 h before MCAO. Brain ischemia achieved by 60 minutes MCAO followed by 24 h reperfusion.
</p><p>
<italic>Group III </italic>(candesartan pretreated ischemic rats with 0.1 mg/kg; n=12): rats received a single IV injection of 0.1 mg/kg of candesartan (Toronto Research Chemical Inc, Canada) 1 h prior to MCAO. All procedures, which were performed on rats of group II, were also repeated for this group.
</p><p>
<italic>Group IV </italic>(candesartan pretreated ischemic rats with 0.5 mg/kg; n=12): rats of this group received a single IV injection of 0.5 mg/kg of candesartan 1 h before induction of MCAO. Other procedures were similar to groups II and III.
</p><p>
In some randomly selected rats from each group (n=4), the tail artery was cannulated to record mean arterial blood pressure (MAP) and withdrew 0.3 ml arterial blood for the measurements of physiological parameters including <italic>p</italic>H, <italic>
P<sub>O</sub></italic><sub>2</sub>, <italic>P</italic><sub>CO2</sub>, Sa<sub>O2</sub> and blood glucose. Blood sampling was done at 10 minutes before and 30 minutes after MCAO and 10 minutes after the start of reperfusion. Other animals from each group (n=8) were used for the determination of neurological outcome, infarct size and tissue swelling.
</p><p>Induction of Transient Focal Cerebral Ischemia</p><p>
Transient focal cerebral ischemia induced by occluding the middle cerebral artery (MCA) using the intraluminal filament method described previously.<sup><xref rid="B16" ref-type="bibr">16</xref></sup> In brief, a midline incision was performed in the ventral surface of the neck. Afterwards, the right common carotid artery (CCA) was freed from surrounding fascia and vagus nerve dissected to reach the bifurcation of external and internal carotid arteries. The occipital artery and superior thyroid branches of the external carotid artery (ECA) were isolated and closed. Subsequently, ECA was ligated permanently and the internal carotid artery (ICA) dissected free to the level of pterygopalatine artery. Afterwards, a poly-L-Lysine coated nylon 3-0 monofilament thread was inserted, via proximal ECA, into ICA and gently moved forward to the circle of Willis to reach and occlude MCA. After 60 minutes ischemia, reperfusion was established by pulling out the nylon thread. After reperfusion phase, the vessels were then tied up and the incisions were sutured. The animals were allowed to recover from anesthesia, and were then kept in separate cages. Twenty-four hours after termination of MCAO, neurological activity was evaluated and animals were then sacrificed under deep anesthesia by a bolus of injection of sodium thiopental solution. The brain was removed and prepared for the determination of the infarct volumes.
</p><p>Measurement of Infarct Size and Tissue Swelling</p><p>
The brain was gently removed and placed in ice-cold saline for 5 minutes to solidify for coronal sectioning using a brain matrix. The brain was sectioned into six 2-mm-thick slices. The slices were stained by immersing in 10 ml 2% Triphenyltetrazolium chloride (TTC) solution, which had been placed in a water bath of 37&#x000b0;C for 30 minutes. The stained slices were kept in 10% buffered formalin for 24 hours. Afterwards, the slices were photographed with a digital camera connected to a PC computer. Infarct area of each slice was measured in mm<sup>2</sup> using an Image Analyzer Software (NIH Image Analyzer). The infarct volume in mm<sup>3</sup> of each slice was calculated by multiplying the obtained infarct areas by the slice thickness. Finally, the infarct volumes of six slices were summed up to calculate the total infarct size of each brain.<sup><xref rid="B17" ref-type="bibr">17</xref></sup> Since brain edema could significantly affect the accuracy of the estimation of the infarct volumes, the calculated infarct volumes were then corrected for brain edema according to equation 1. The tissue swelling induced in the lesioned hemispheres of the TTC staining method was evaluated as in equation 2.<sup><xref rid="B15" ref-type="bibr">15</xref></sup>
</p><p>(1) Corrected infarction volume=[NHV&#x02013;(LHV&#x02013;MLV)]</p><p>(2) %Tissue swelling=[(LHV&#x02013;NHV)/NHV] &#x000d7;100 </p><p>NHV: Non-lesioned hemisphere volume (left hemisphere)</p><p>LHV: Lesioned hemisphere volume (right hemisphere)</p><p>MLV: Measured lesion volume</p><p>Statistical Analysis</p><p>All statistical analyses were performed by SPSS software (SPSS for Windows version 20) Most of the data are presented as mean&#x000b1;SEM and the significance of differences was evaluated using one-way analysis of variance (ANOVA) followed by Tukey&#x02019;s test. Neurological deficit values are given as median values with quartile range (25-75%). Significant differences were analyzed by Kruskal&#x02013;Wallis one-way ANOVA test. Statistical significance was accepted at P&#x0003c;0.05. </p></sec><sec sec-type="results"><title>Results</title><p>Physiological Parameters</p><p>
The physiological parameters measured in this study such as P<sub>aO2</sub>, S<sub>a</sub>O<sub>2</sub>, P<sub>a</sub>CO<sub>2</sub>, pH, blood glucose, head and core temperatures are summarized in <xref ref-type="table" rid="T1">table 1</xref>. There was no significant difference between these parameters using intra-groups or inter-groups comparison.
</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Physiological parameters in the studied groups</p></caption><table frame="hsides" rules="all"><thead><tr><th style=" color:#000000;" align="left" valign="middle" rowspan="2" colspan="1">
<bold>Parameters Name</bold>
</th><th style=" color:#000000;" align="left" colspan="3" valign="middle" rowspan="1">
<bold>Pre ischemia</bold>
</th><th style=" color:#000000;" align="left" colspan="3" valign="middle" rowspan="1">
<bold>During Occlusion</bold>
</th><th style=" color:#000000;" align="left" colspan="3" valign="middle" rowspan="1">
<bold>During Reperfusion</bold>
</th></tr><tr><th style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>group II</bold>
</th><th style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>group III</bold>
</th><th style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>group IV</bold>
</th><th style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>group II</bold>
</th><th style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>group III</bold>
</th><th style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>group IV</bold>
</th><th style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>group II</bold>
</th><th style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>group III</bold>
</th><th style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>group IV</bold>
</th></tr></thead><tbody><tr><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
PaO<sub>2(mmHg)</sub>
</td><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 116&#x000b1; 8 </td><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 105&#x000b1;21 </td><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 127&#x000b1;11 </td><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 103&#x000b1;11 </td><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 105&#x000b1;5 </td><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 110&#x000b1;15 </td><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 114&#x000b1;9 </td><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 114&#x000b1;11 </td><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 104&#x000b1;12 </td></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
SaO<sub>2(%)</sub>
</td><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 98&#x000b1;0.4 </td><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 96.5&#x000b1;1.3 </td><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 98.3&#x000b1;0.4 </td><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 96.7&#x000b1;1 </td><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 97.3&#x000b1;0.3 </td><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 96.6&#x000b1;1.8 </td><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 97.8&#x000b1;0.5 </td><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 97.9&#x000b1;0.6 </td><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 96.3&#x000b1;1.8 </td></tr><tr><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1">
PaCO<sub>2(mmHg)</sub>
</td><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 42.5&#x000b1;0.7 </td><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 40&#x000b1;2.8 </td><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 42.1&#x000b1;1.4 </td><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 40.2&#x000b1;0.7 </td><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 39.9&#x000b1;2.2 </td><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 39&#x000b1;2 </td><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 41.1&#x000b1;1.6 </td><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 41.1&#x000b1;2 </td><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 41.2&#x000b1;1.6 </td></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> pH </td><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 7.32&#x000b1;0.01 </td><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 7.33&#x000b1;0.01 </td><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 7.31&#x000b1;0.01 </td><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 7.3&#x000b1;0.01 </td><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 7.31&#x000b1;0.01 </td><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 7.3&#x000b1;0.02 </td><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 7.3&#x000b1;0.01 </td><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 7.32&#x000b1;0.01 </td><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 7.29&#x000b1;0.01 </td></tr><tr><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> Blood Glucose (mg/dl) </td><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 137&#x000b1;15 </td><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 141&#x000b1;10 </td><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 124&#x000b1;17 </td><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 129&#x000b1;10 </td><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 135&#x000b1;9 </td><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 121&#x000b1;16 </td><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 133&#x000b1;8 </td><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 142&#x000b1;14 </td><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 122&#x000b1;18 </td></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> Body Temperature </td><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 37.1&#x000b1;0.06 </td><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 37.3&#x000b1;0.15 </td><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 37.3&#x000b1;0.14 </td><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 37.4&#x000b1;0.1 </td><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 37.4&#x000b1;0.09 </td><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 37&#x000b1;0.05 </td><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 37.2&#x000b1;0.1 </td><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 37.5&#x000b1;0.09 </td><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 37.4&#x000b1;0.09 </td></tr><tr><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> Head Temperature </td><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 37.1&#x000b1;0.05 </td><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 37.4&#x000b1;0.1 </td><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 37.4&#x000b1;0.13 </td><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 37.5&#x000b1;0.09 </td><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 37.4&#x000b1;0.08 </td><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 37.5&#x000b1;0.1 </td><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 37.4&#x000b1;0.1 </td><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 37.5&#x000b1;0.05 </td><td style="background-color:#F0F0FA; color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 37.5&#x000b1;0.09 </td></tr><tr><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> MAP (mmHg) </td><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 91.9&#x000b1;3 </td><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 78.3&#x000b1;5 </td><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 57&#x000b1;11* </td><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 92.3&#x000b1;2 </td><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 83.5&#x000b1;5 </td><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 69&#x000b1;3 </td><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 92&#x000b1;3 </td><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 74.5&#x000b1;8 </td><td style=" color:#000000;" align="left" valign="middle" rowspan="1" colspan="1"> 68.4&#x000b1; 9 </td></tr></tbody></table><table-wrap-foot><p>Values are mean&#x000b1;SEM of four rats in each group; *Significant compared with the respective control rats (group II), P&#x0003c;0.05. MAP: mean arterial blood pressure</p></table-wrap-foot></table-wrap><p>Mean Arterial Blood Pressure</p><p>
There was no significant difference among the mean arterial blood pressure (MAP) of ischemia reperfused (IR) rats received vehicle (group II) or candesartan at 0.1 mg/kg (group III) at 10 minutes before MCAO, 30 minutes after MCAO or 10 minutes after the onset of reperfusion. Whereas the MAP of IR rats received candesartan at 0.5 mg/kg (group IV) were significantly lower than those of IR rats received vehicle only at 10 minutes before MCAO (P=0.03, <xref ref-type="table" rid="T1">table 1</xref>).
</p><p>Neurological Deficit Score (NDS) </p><p>The NDS of IR rats received vehicle were significantly higher than that of sham-operated rats. However, there were significant improvements in NDS of ischemic rats treated with 0.1 mg/kg or 0.5 mg/kg of candesartan. The median (25&#x02013;75% quartile range) of the total deficit score for control ischemic rats (group II) was 3 (2&#x02013;3) compared with 1 (1.0&#x02013;2) in group III (P=0.008) and 1 (1.0&#x02013;2) in group IV (P=0.003) that received candesartan at 0.1 mg/kg or 0.5 mg/kg respectively (Kruskal&#x02013;Wallis one-way ANOVA test).</p><p>Cerebral Infarct size </p><p>
The sham-operated rats had no cerebral infarction. In comparison with cerebral total infarct size of IR rats received vehicle (group II: 292&#x000b1;21 mm<sup>3</sup>), IR rats received candesartan at 0.1 or 0.5 mg/kg had significantly lower total infarct size (group III: 136&#x000b1;21 mm<sup>3</sup> P=0.001, and group IV: 138&#x000b1;24 mm<sup>3 </sup>respectively, P=0.001, <xref ref-type="fig" rid="F1">figure 1</xref>). Furthermore, pre-ischemic AT1 receptor blockade with candesartan at 0.1 or 0.5 mg/kg, significantly reduced cortical and striatal infarction sizes compared to IR rats received vehicle (P=0.001 for both <xref ref-type="fig" rid="F2">figure 2</xref> and <xref ref-type="fig" rid="F3">figure 3</xref>).
</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Tissue swelling (a) and total infarct size (b) in the studied groups. Values are mean&#x000b1;SEM of eight rats in each group. *P&#x0003c;0.05, **P&#x0003c;0.001 significant as compared with the respective vehicle-treated control rats (group II).</p></caption><graphic xlink:href="ijms-39-536-g001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><p>Representative brain slices stained with TTC in the studied groups. Ischemic regions are white and non-ischemic regions are red colored.</p></caption><graphic xlink:href="ijms-39-536-g002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><p>Cortical (a) and striatal (b) infarct sizes in the studied groups. Values are mean&#x000b1;SEM of eight rats in each group. *P&#x0003c;0.01 significant as compared with vehicle-treated control rats (group II).</p></caption><graphic xlink:href="ijms-39-536-g003"/></fig><p>Tissue Swelling</p><p>
Occurring ischemia produced considerable tissue swelling in IR rats received vehicle (group II: 12.4&#x000b1;1.1%). Pre-ischemic AT1 receptor blockade with candesartan significantly decreased tissue swelling by 47.6 % at 0.1 mg/kg (group III, P=0.04) and 53.6% at 0.5 mg/kg (group IV, P=0.02) respectively (<xref ref-type="fig" rid="F1">figure 1</xref>).
</p></sec><sec sec-type="discussion"><title>Discussion</title><p>
The results of this study revealed that the blockade of AT<sub>1</sub> receptors, reduced cortical and striatal infarct sizes and improved neurological motor deficits. These findings are in agreement with reports from other investigators demonstrating that AT<sub>1</sub> receptor blockade with candesartan reduced infarct size in transient cerebral ischemia in normotensive rats,<sup><xref rid="B18" ref-type="bibr">18</xref></sup> or permanent focal ischemia in adult spontaneously hypertensive rats.<sup><xref rid="B15" ref-type="bibr">15</xref></sup> Transient or permanent MCA occlusion in AT<sub>1</sub> knockout mice, as compared with normal type, produced smaller core in the ischemic area with a much larger penumbra.<sup><xref rid="B19" ref-type="bibr">19</xref></sup> In contrast, Groth et al.<sup><xref rid="B20" ref-type="bibr">20</xref></sup> and Sugawara et al.<sup><xref rid="B21" ref-type="bibr">21</xref></sup> reported that inhibition of AT<sub>1</sub> receptors by pretreatment of the animal with candesartan did not reduce ischemic brain injuries in the rat. This controversy is believed to be related to hypotension observed before, during and after ischemia.<sup><xref rid="B20" ref-type="bibr">20</xref></sup> The present study also showed that the protective effects of candesartan against brain injuries and edema at high dose (0.5 mg/kg) was not significantly different with non-hypotensive dose of this drug (0.1 mg/kg). Candesartan at 0.5 mg/kg could significantly decrease MAP before ischemia. During cerebral ischemia, the mechanisms regulating CBF are impaired leaving the dependency of local CBF on arterial blood pressure.<sup><xref rid="B22" ref-type="bibr">22</xref></sup> Hence severe hypotension, possibly did mask the protective effects of AT<sub>1</sub> receptor blockade. It seems that there is a positive correlation between the level of MAP and the protective effects of AT<sub>1</sub> receptor blockade and profound drop in MAP hypoperfuses the ischemic area of the brain and prevent the protective effects of AT<sub>1</sub> receptor blockade against IR injuries.
</p><p>
Various mechanisms might be responsible for the beneficial effects of AT<sub>1</sub> receptor blockade in brain ischemia. Such effects might be partly attributed to their stabilization actions on the impaired cerebrovascular autoregulation in penumbra. In addition, they might be due to effects on the nucleus solitary tract that contributes to the regulation of CBF by a reduction of central sympathetic tone.<sup><xref rid="B23" ref-type="bibr">23</xref></sup> Anti-apoptotic mechanisms might be involved in the protective effects of AT<sub>1</sub> receptor blockade. Ang II, via activation of AT<sub>1</sub> receptors, may provoke apoptosis of ischemic neurons.<sup><xref rid="B24" ref-type="bibr">24</xref></sup> Thus, anti- apoptotic effects of AT<sub>1 </sub>receptor blockade may have beneficial effects on ischemic brain injury.
</p><p>
The beneficial effects of AT<sub>1</sub> blockade might also be attributed to the reduction of reactive oxygen species (ROS) production.<sup><xref rid="B21" ref-type="bibr">21</xref></sup> Cerebral ischemia is associated with excessive production of ROS, especially superoxide. The production of ROS initiates chain reactions causing cellular macromolecular damage, and promotes the mitochondrial apoptosis pathway, which ultimately leads to cell death.<sup><xref rid="B25" ref-type="bibr">25</xref></sup>The stimulation of AT<sub>2</sub> receptors might also be involved in the beneficial effects of AT<sub>1</sub> receptor blockade. The blockade of AT<sub>1</sub> receptors may slow down the neurodegenerative events in ischemic brain tissues by allowing Ang II to increase the stimulation of AT<sub>2</sub> receptors.<sup><xref rid="B26" ref-type="bibr">26</xref></sup>
</p><p>
Brain edema is a life&#x02013;threatening complication of cerebral infarction and aggravates the primary ischemic injury to the brain by negatively affecting the perfusion of penumbra due to the compression of cerebral vasculature via increased intracranial pressure and herniation.<sup><xref rid="B2" ref-type="bibr">2</xref></sup><sup>,</sup><sup><xref rid="B3" ref-type="bibr">3</xref></sup> The results of the present study demonstrated that induction of focal cerebral ischemia significantly increased tissue swelling of ischemic hemisphere. While, pre-ischemic blocking of AT<sub>1</sub> receptors by candesartan significantly reduced swelling in the ischemic hemisphere and decreased ischemic edema. Other reports about the evaluation of tissue swelling of the ischemic hemispheres, from TTC method<sup><xref rid="B15" ref-type="bibr">15</xref></sup><sup>,</sup><sup><xref rid="B23" ref-type="bibr">23</xref></sup><sup>,</sup><sup><xref rid="B27" ref-type="bibr">27</xref></sup> supports the results of the present study. The protective effects of AT<sub>1</sub> receptor blockade on ischemic brain edema were demonstrated in other experimental models and animal species. Blezer and colleagues showed that AT<sub>1</sub> receptor inhibition by non-hypotensive dose of losartan reduced cerebral edema and markedly prolonged survival in SHR.<sup><xref rid="B28" ref-type="bibr">28</xref></sup> In addition, the inhibition of AT<sub>1</sub> receptors by losartan prevented brain edema following global cerebral ischemia in the cat.<sup><xref rid="B29" ref-type="bibr">29</xref></sup> These results support the conclusions of the present study that Ang II and AT<sub>1</sub> receptors might be involved in the formation of brain edema during I/R injuries.
</p><p>
The mechanisms of the beneficial effects of AT<sub>1</sub> receptor blockade on ischemic brain edema have not been fully elucidated. It seems that non-hypotensive mechanisms play a major role, since the present study as well as others<sup><xref rid="B28" ref-type="bibr">28</xref></sup><sup>,</sup><sup><xref rid="B29" ref-type="bibr">29</xref></sup> showed that the protective effects of AT<sub>1</sub> receptor blockade was achieved without hypotension. Mechanisms such as normalizing of endothelial NO synthase activity, and reduced cerebrovascular inflammation might also be involved in such protective effects.<sup><xref rid="B30" ref-type="bibr">30</xref></sup> Furthermore, Ang II via AT<sub>1</sub> receptors may enhance cerebrovascular permeability and edema by production of ROS and matrix metalloproteinases.<sup><xref rid="B31" ref-type="bibr">31</xref></sup><sup>,</sup><sup><xref rid="B32" ref-type="bibr">32</xref></sup> Thus, blocking of AT<sub>1</sub> receptors, may reduce ischemic edema by the protective effects on BBB integrity and lowering its permeability during ischemia. However, the clarification of this postulation needs more study.
</p></sec><sec sec-type="conclusion"><title>Conclusion</title><p>
The results of this study demonstrate that RAS participates in the exacerbation of cerebral I/R injuries, and Ang II may play an important role as mediator in ischemic brain injury by stimulating of AT<sub>1</sub> receptors. Hence, the inhibition of RAS by an AT<sub>1</sub> receptor blocker reduced cerebral infarction size, tissue swelling and improved neurological motor activity in rats exposed to transient MCA occlusion.
</p></sec></body><back><ack><title>Acknowledgment</title><p>The authors cordially appreciate the help of Dr Sabet Ghadam Jahromi of Toronto University, Canada, for providing us with candesartan and Dr Abedin Vakili of Semnan University of Medical Sciences for his valuable advices.</p></ack><sec><title/><p>
<bold>Conflict of Interest:</bold> None declared.
</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wang-Fischer</surname><given-names>Y</given-names></name></person-group><source>Manual of stroke models in rats</source><year>2009</year><publisher-loc>New York</publisher-loc><publisher-name>CRC Press</publisher-name></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marmarou</surname><given-names>A</given-names></name></person-group><article-title>A review of progress in understanding the pathophysiology and treatment of brain edema</article-title><source> Neurosurg Focus</source><year>2007</year><volume>22</volume><fpage>E1</fpage><comment>doi: 10.3171/foc.2007.22.5.2. PubMed PMID: 17613227</comment><?supplied-pmid 17613227?><pub-id pub-id-type="pmid">17613227</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Su</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>QP</given-names></name></person-group><article-title>Aquaporin-4 and traumatic brain edema</article-title><source> Chin J Traumatol</source><year>2010</year><volume>13</volume><fpage>103</fpage><lpage>10</lpage><comment>PubMed PMID: 20356447</comment><?supplied-pmid 20356447?><pub-id pub-id-type="pmid">20356447</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>F</given-names></name><name><surname>Xiang</surname><given-names>Z</given-names></name><name><surname>Feng</surname><given-names>WX</given-names></name><name><surname>Zhen</surname><given-names>LX</given-names></name></person-group><article-title>Neuronal free Ca(2+)and BBB permeability and ultrastructure in head injury with secondary insult</article-title><source> J Clin Neurosci</source><year>2001</year><volume>8</volume><fpage>561</fpage><lpage>3</lpage><comment>doi: 10.1054/jocn.2001.0980. PubMed PMID: 11683606</comment><?supplied-pmid 11683606?><pub-id pub-id-type="pmid">11683606</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gavras</surname><given-names>H</given-names></name><name><surname>Brunner</surname><given-names>HR</given-names></name></person-group><article-title>Role of angiotensin and its inhibition in hypertension, ischemic heart disease, and heart failure</article-title><source> Hypertension</source><year>2001</year><volume>37</volume><fpage>342</fpage><lpage>5</lpage><comment>doi: 10.1161/01.hyp.37.2.342. PubMed PMID: 11230297</comment><?supplied-pmid 11230297?><pub-id pub-id-type="pmid">11230297</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lerman</surname><given-names>LO</given-names></name><name><surname>Textor</surname><given-names>SC</given-names></name><name><surname>Grande</surname><given-names>JP</given-names></name></person-group><article-title>Mechanisms of tissue injury in renal artery stenosis: ischemia and beyond</article-title><source> Prog Cardiovasc Dis</source><year>2009</year><volume>52</volume><fpage>196</fpage><lpage>203</lpage><comment>doi: 10.1016/j.pcad.2009.09.002. PubMed PMID: 19917330; PubMed Central PMCID: PMC2800096</comment><?supplied-pmid 19917330?><pub-id pub-id-type="pmid">19917330</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Th&#x000f6;ne-Reineke</surname><given-names>C</given-names></name><name><surname>Zimmermann</surname><given-names>M</given-names></name><name><surname>Neumann</surname><given-names>C</given-names></name><name><surname>Krikov</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Gerova</surname><given-names>N</given-names></name><etal/></person-group><article-title>Are angiotensin receptor blockers neuroprotective?</article-title><source> Curr Hypertens Rep</source><year>2004</year><volume>6</volume><fpage>257</fpage><lpage>66</lpage><comment>doi: 10.1007/s11906-004-0019-3. PubMed PMID: 15257859</comment><?supplied-pmid 15257859?><pub-id pub-id-type="pmid">15257859</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panahpour</surname><given-names>H</given-names></name><name><surname>Dehghani</surname><given-names>GA</given-names></name></person-group><article-title>Inhibition of central angiotensin-converting enzyme with enalapril protects the brain from ischemia/reperfusion injury in normotensive rat</article-title><source> Daru</source><year>2010</year><volume>18</volume><fpage>35</fpage><lpage>40</lpage><comment>PubMed PMID: 22615591; PubMed Central PMCID: PMC3232089</comment><?supplied-pmid 22615591?><pub-id pub-id-type="pmid">22615591</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panahpour</surname><given-names>H</given-names></name><name><surname>Dehghani</surname><given-names>GA</given-names></name></person-group><article-title>Attenuation of focal cerebral ischemic injury following post-ischemic inhibition of angiotensin converting enzyme (ACE) activity in normotensive rat</article-title><source> Iran Biomed J</source><year>2012</year><volume>16</volume><fpage>202</fpage><lpage>8</lpage><comment>PubMed PMID: 23183619; PubMed Central PMCID: PMC3600966</comment><?supplied-pmid 23183619?><pub-id pub-id-type="pmid">23183619</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Gasparo</surname><given-names>M</given-names></name><name><surname>Catt</surname><given-names>KJ</given-names></name><name><surname>Inagami</surname><given-names>T</given-names></name><name><surname>Wright</surname><given-names>JW</given-names></name><name><surname>Unger</surname><given-names>T</given-names></name></person-group><article-title>International union of pharmacology. XXIII. The angiotensin II receptors</article-title><source> Pharmacol Rev</source><year>2000</year><volume>52</volume><fpage>415</fpage><lpage>72</lpage><comment>PubMed PMID: 10977869</comment><?supplied-pmid 10977869?><pub-id pub-id-type="pmid">10977869</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Culman</surname><given-names>J</given-names></name><name><surname>Blume</surname><given-names>A</given-names></name><name><surname>Gohlke</surname><given-names>P</given-names></name><name><surname>Unger</surname><given-names>T</given-names></name></person-group><article-title>The renin-angiotensin system in the brain: possible therapeutic implications for AT(1)-receptor blockers</article-title><source> J Hum Hypertens</source><year>2002</year><volume>16</volume><fpage>S64</fpage><lpage>70</lpage><comment>doi: 10.1038/sj.jhh.1001442. PubMed PMID: 12140731</comment><?supplied-pmid 12140731?><pub-id pub-id-type="pmid">12140731</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gohlke</surname><given-names>P</given-names></name><name><surname>Von K&#x000fc;gelgen</surname><given-names>S</given-names></name><name><surname>J&#x000fc;rgensen</surname><given-names>T</given-names></name><name><surname>Kox</surname><given-names>T</given-names></name><name><surname>Rascher</surname><given-names>W</given-names></name><name><surname>Culman</surname><given-names>J</given-names></name><etal/></person-group><article-title>Effects of orally applied candesartan cilexetil on central responses to angiotensin II in conscious rats</article-title><source> J Hypertens</source><year>2002</year><volume>20</volume><fpage>909</fpage><lpage>18</lpage><comment>doi: 10.1097/00004872-200205000-00026. PubMed PMID: 12011652</comment><?supplied-pmid 12011652?><pub-id pub-id-type="pmid">12011652</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takemori</surname><given-names>K</given-names></name><name><surname>Inoue</surname><given-names>T</given-names></name><name><surname>Ito</surname><given-names>H</given-names></name></person-group><article-title>Effects of angiotensin II type 1 receptor blocker and adiponectin on adipocyte dysfunction in stroke-prone spontaneously hypertensive rats</article-title><source> Lipids Health Dis</source><year>2013</year><volume>12</volume><fpage>108</fpage><comment>doi: 10.1186/1476-511x-12-108. PubMed PMID: 23876211; PubMed Central PMCID: PMC3750705</comment><?supplied-pmid 23876211?><pub-id pub-id-type="pmid">23876211</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Pavel</surname><given-names>J</given-names></name><name><surname>Macova</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>ZX</given-names></name><name><surname>Imboden</surname><given-names>H</given-names></name><name><surname>Ge</surname><given-names>L</given-names></name><etal/></person-group><article-title>AT1 receptor blockade regulates the local angiotensin II system in cerebral microvessels from spontaneously hypertensive rats</article-title><source> Stroke</source><year>2006</year><volume>37</volume><fpage>1271</fpage><lpage>6</lpage><comment>doi: 10.1161/01.str.0000217404.64352.d7. PubMed PMID: 16601219</comment><?supplied-pmid 16601219?><pub-id pub-id-type="pmid">16601219</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>T</given-names></name><name><surname>Yamakawa</surname><given-names>H</given-names></name><name><surname>Bregonzio</surname><given-names>C</given-names></name><name><surname>Terr&#x000f3;n</surname><given-names>JA</given-names></name><name><surname>Falc&#x000f3;n-Neri</surname><given-names>A</given-names></name><name><surname>Saavedra</surname><given-names>JM</given-names></name></person-group><article-title>Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist</article-title><source> Stroke</source><year>2002</year><volume>33</volume><fpage>2297</fpage><lpage>303</lpage><comment>doi: 10.1161/01.str.0000027274.03779.f3. PubMed PMID: 12215602</comment><?supplied-pmid 12215602?><pub-id pub-id-type="pmid">12215602</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panahpour</surname><given-names>H</given-names></name><name><surname>Nekooeian</surname><given-names>AA</given-names></name><name><surname>Dehghani</surname><given-names>GA</given-names></name></person-group><article-title>Inhibition of angiotensin-converting enzyme reduces cerebral infarction size in experimental-induced focal cerebral ischemia in the rat</article-title><source> Iran J Med Sci</source><year>2007</year><volume>32</volume><fpage>12</fpage><lpage>17</lpage></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vakili</surname><given-names>A</given-names></name><name><surname>Nekooeian</surname><given-names>AA</given-names></name><name><surname>Dehghani</surname><given-names>GA</given-names></name></person-group><article-title>L-NAME and 7-Nitroindazole Reduces Brain Injuries in Transient Focal Cerebral Ischemia in the Rat</article-title><source> Iran J Med Sci</source><year>2004</year><volume>29</volume><fpage>109</fpage><lpage>115</lpage></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engelhorn</surname><given-names>T</given-names></name><name><surname>Goerike</surname><given-names>S</given-names></name><name><surname>Doerfler</surname><given-names>A</given-names></name><name><surname>Okorn</surname><given-names>C</given-names></name><name><surname>Forsting</surname><given-names>M</given-names></name><name><surname>Heusch</surname><given-names>G</given-names></name><etal/></person-group><article-title>The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats</article-title><source> J Cereb Blood Flow Metab</source><year>2004</year><volume>24</volume><fpage>467</fpage><lpage>74</lpage><comment>doi: 10.1097/00004647-200404000-00012. PubMed PMID: 15087716</comment><?supplied-pmid 15087716?><pub-id pub-id-type="pmid">15087716</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walther</surname><given-names>T</given-names></name><name><surname>Olah</surname><given-names>L</given-names></name><name><surname>Harms</surname><given-names>C</given-names></name><name><surname>Maul</surname><given-names>B</given-names></name><name><surname>Bader</surname><given-names>M</given-names></name><name><surname>H&#x000f6;rtnagl</surname><given-names>H</given-names></name><etal/></person-group><article-title>Ischemic injury in experimental stroke depends on angiotensin II</article-title><source> FASEB J</source><year>2002</year><volume>16</volume><fpage>169</fpage><lpage>76</lpage><comment>doi: 10.1096/fj.01-0601com. PubMed PMID: 11818364</comment><?supplied-pmid 11818364?><pub-id pub-id-type="pmid">11818364</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Groth</surname><given-names>W</given-names></name><name><surname>Blume</surname><given-names>A</given-names></name><name><surname>Gohlke</surname><given-names>P</given-names></name><name><surname>Unger</surname><given-names>T</given-names></name><name><surname>Culman</surname><given-names>J</given-names></name></person-group><article-title>Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats</article-title><source> J Hypertens</source><year>2003</year><volume>21</volume><fpage>2175</fpage><lpage>82</lpage><comment>doi: 10.1097/00004872-200311000-00028. PubMed PMID: 14597862</comment><?supplied-pmid 14597862?><pub-id pub-id-type="pmid">14597862</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugawara</surname><given-names>T</given-names></name><name><surname>Kinouchi</surname><given-names>H</given-names></name><name><surname>Oda</surname><given-names>M</given-names></name><name><surname>Shoji</surname><given-names>H</given-names></name><name><surname>Omae</surname><given-names>T</given-names></name><name><surname>Mizoi</surname><given-names>K</given-names></name></person-group><article-title>Candesartan reduces superoxide production after global cerebral ischemia</article-title><source> Neuroreport</source><year>2005</year><volume>16</volume><fpage>325</fpage><lpage>8</lpage><comment>doi: 10.1097/00001756-200503150-00004. PubMed PMID: 15729131</comment><?supplied-pmid 15729131?><pub-id pub-id-type="pmid">15729131</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saavedra</surname><given-names>JM</given-names></name><name><surname>Ito</surname><given-names>T</given-names></name><name><surname>Nishimura</surname><given-names>Y</given-names></name></person-group><article-title>The role of angiotensin II AT1-receptors in the regulation of the cerebral blood flow and brain ischaemia</article-title><source> J Renin Angiotensin Aldosterone Syst</source><year>2001</year><volume>2</volume><fpage>S102</fpage><lpage>S109</lpage><comment>doi: 10.1177/14703203010020011801</comment></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishimura</surname><given-names>Y</given-names></name><name><surname>Ito</surname><given-names>T</given-names></name><name><surname>Saavedra</surname><given-names>JM</given-names></name></person-group><article-title>Angiotensin II AT(1) blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats</article-title><source> Stroke</source><year>2000</year><volume>31</volume><fpage>2478</fpage><lpage>86</lpage><comment>doi: 10.1161/01.str.31.10.2478. PubMed PMID: 11022082</comment><?supplied-pmid 11022082?><pub-id pub-id-type="pmid">11022082</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lou</surname><given-names>M</given-names></name><name><surname>Blume</surname><given-names>A</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Gohlke</surname><given-names>P</given-names></name><name><surname>Deuschl</surname><given-names>G</given-names></name><name><surname>Herdegen</surname><given-names>T</given-names></name><etal/></person-group><article-title>Sustained blockade of brain AT1 receptors before and after focal cerebral ischemia alleviates neurologic deficits and reduces neuronal injury, apoptosis, and inflammatory responses in the rat</article-title><source> J Cereb Blood Flow Metab</source><year>2004</year><volume>24</volume><fpage>536</fpage><lpage>47</lpage><comment>doi: 10.1097/00004647-200405000-00008. PubMed PMID: 15129186</comment><?supplied-pmid 15129186?><pub-id pub-id-type="pmid">15129186</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>JW</given-names></name><name><surname>Narayanan</surname><given-names>SV</given-names></name><name><surname>Perez-Pinzon</surname><given-names>MA</given-names></name></person-group><article-title>Redox signaling pathways involved in neuronal ischemic preconditioning</article-title><source> Curr Neuropharmacol</source><year>2012</year><volume>10</volume><fpage>354</fpage><lpage>69</lpage><comment>doi: 10.2174/157015912804143577. PubMed PMID: 23730259; PubMed Central PMCID: PMC3520045</comment><?supplied-pmid 23730259?><pub-id pub-id-type="pmid">23730259</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faure</surname><given-names>S</given-names></name><name><surname>Bureau</surname><given-names>A</given-names></name><name><surname>Oudart</surname><given-names>N</given-names></name><name><surname>Javellaud</surname><given-names>J</given-names></name><name><surname>Fournier</surname><given-names>A</given-names></name><name><surname>Achard</surname><given-names>JM</given-names></name></person-group><article-title>Protective effect of candesartan in experimental ischemic stroke in the rat mediated by AT2 and AT4 receptors</article-title><source> J Hypertens</source><year>2008</year><volume>26</volume><fpage>2008</fpage><lpage>15</lpage><comment>doi: 10.1097/HJH.0b013e32830dd5ee. PubMed PMID: 18806625</comment><?supplied-pmid 18806625?><pub-id pub-id-type="pmid">18806625</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brdon</surname><given-names>J</given-names></name><name><surname>Kaiser</surname><given-names>S</given-names></name><name><surname>Hagemann</surname><given-names>F</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Culman</surname><given-names>J</given-names></name><name><surname>Gohlke</surname><given-names>P</given-names></name></person-group><article-title>Comparison between early and delayed systemic treatment with candesartan of rats after ischaemic stroke</article-title><source> J Hypertens</source><year>2007</year><volume>25</volume><fpage>187</fpage><lpage>96</lpage><comment>doi: 10.1097/01.hjh.0000254376.80864.d3. PubMed PMID: 17143191</comment><?supplied-pmid 17143191?><pub-id pub-id-type="pmid">17143191</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blezer</surname><given-names>EL</given-names></name><name><surname>Nicolay</surname><given-names>K</given-names></name><name><surname>Koomans</surname><given-names>HA</given-names></name><name><surname>Joles</surname><given-names>JA</given-names></name></person-group><article-title>Losartan versus enalapril on cerebral edema and proteinuria in stroke-prone hypertensive rats</article-title><source> Am J Hypertens</source><year>2001</year><volume>14</volume><fpage>54</fpage><lpage>61</lpage><comment>doi: 10.1161/01.str.29.8.1671. PubMed PMID: 11206680</comment><?supplied-pmid 11206680?><pub-id pub-id-type="pmid">11206680</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asiedu-Gyekye</surname><given-names>IJ</given-names></name><name><surname>Antwi</surname><given-names>DA</given-names></name></person-group><article-title>Does losartan prevent cerebral edema? A preliminary study using a vascular compartment model</article-title><source> Med Sci Monit</source><year>2003</year><volume>9</volume><fpage>BR127</fpage><lpage>30</lpage><comment>doi: 10.4314/dai.v15i3.15643. PubMed PMID: 12640335</comment><?supplied-pmid 12640335?><pub-id pub-id-type="pmid">12640335</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saavedra</surname><given-names>JM</given-names></name></person-group><article-title>Brain angiotensin II: new developments, unanswered questions and therapeutic opportunities</article-title><source> Cell Mol Neurobiol</source><year>2005</year><volume>25</volume><fpage>485</fpage><lpage>512</lpage><comment>doi: 10.1007/s10571-005-4011-5. PubMed PMID: 16075377</comment><?supplied-pmid 16075377?><pub-id pub-id-type="pmid">16075377</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>H</given-names></name><name><surname>Hosomi</surname><given-names>N</given-names></name><name><surname>Pelisch</surname><given-names>N</given-names></name><name><surname>Nakano</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Ueno</surname><given-names>M</given-names></name><etal/></person-group><article-title>Therapeutic effects of postischemic treatment with hypotensive doses of an angiotensin II receptor blocker on transient focal cerebral ischemia</article-title><source> J Hypertens</source><year>2011</year><volume>29</volume><fpage>2210&#x02013;19</fpage><comment>doi: 10.1097/hjh.0b013e32834bbb30. PubMed PMID: 21934531</comment><?supplied-pmid 21934531?><pub-id pub-id-type="pmid">21934531</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hosomi</surname><given-names>N</given-names></name><name><surname>Nishiyama</surname><given-names>A</given-names></name><name><surname>Ban</surname><given-names>CR</given-names></name><name><surname>Naya</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Kohno</surname><given-names>M</given-names></name><etal/></person-group><article-title>Angiotensin type 1 receptor blockage improves ischemic injury following transient focal cerebral ischemia</article-title><source> Neuroscience</source><year>2005</year><volume>134</volume><fpage>225</fpage><lpage>31</lpage><comment>doi: 10.1016/j.neuroscience.2005.03.054. PubMed PMID: 15963646</comment><?supplied-pmid 15963646?><pub-id pub-id-type="pmid">15963646</pub-id></element-citation></ref></ref-list></back></article>
